Knowledge Accumulation and Industry Evolution
The Case of Pharma-Biotech
Herausgeber: Dosi, Giovanni; Mazzucato, Mariana
Knowledge Accumulation and Industry Evolution
The Case of Pharma-Biotech
Herausgeber: Dosi, Giovanni; Mazzucato, Mariana
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Explores how the biotechnology and pharmaceutical sector is affected by innovation, growth and public policy.
Andere Kunden interessierten sich auch für
- Innovation, Industry Evolution and Employment29,99 €
- Nicholas Paine GilmanProfit Sharing Between Employer and Employee: A Study in the Evolution of the Wages System29,99 €
- Daniel SusskindA World Without Work16,99 €
- Evolution and Procedures in Central Banking29,99 €
- Frederic L. PryorEconomic Evolution and Structure54,99 €
- Jim StanfordPower, Employment and Accumulation34,99 €
- Abbas AbdelkarimPrimitive Capital Accumulation in the Sudan133,99 €
-
-
-
Explores how the biotechnology and pharmaceutical sector is affected by innovation, growth and public policy.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 468
- Erscheinungstermin: 30. September 2009
- Englisch
- Abmessung: 229mm x 152mm x 27mm
- Gewicht: 754g
- ISBN-13: 9780521124003
- ISBN-10: 052112400X
- Artikelnr.: 27869893
- Verlag: Cambridge University Press
- Seitenzahl: 468
- Erscheinungstermin: 30. September 2009
- Englisch
- Abmessung: 229mm x 152mm x 27mm
- Gewicht: 754g
- ISBN-13: 9780521124003
- ISBN-10: 052112400X
- Artikelnr.: 27869893
Figures; Tables; Contributors; 1. Introduction: innovation, growth and
industry evolution Giovanni Dosi and Mariana Mazzucato; Part I. Innovation
and Industry Evolution: 2. Pharmaceutical innovation as a process of
creative destruction Frank Lichtenberg; 3. The evolution of pharmaceutical
innovation Paul Nightingale and Surya Mahdi; 4. Firm and regional
determinants in innovation models: evidence from biotechnology and
traditional chemicals Myriam Mariani; 5. Comments on Part I Lou Galambos;
Part II. Firm Growth and Market Structure: 6. Growth and diversification
patterns of the worldwide pharmaceutical industry Giulio Bottazzi, Fabio
Paolli and Angelo Secchi; 7. Heterogeneity in the firms' growth process:
the case of the pharmaceutical industry Elena Cefis, Matteo Ciccarelli and
Luigi Orsenigo; 8. Entry, market structure and innovation in a
history-friendly model of the evolution of the pharmaceutical industry
Christian Garavaglia, Franco Malerba and Luigi Orsenigo; 9. Comments on
Part II Boyan Jovanovic; Part III. Policy Implications: 10. Effects of
research tool patents and licensing on biomedical innovation John P. Walsh,
Ashish Arora and Wesley Cohen; 11. Upstream patents and public health: the
case for generic testing of breast cancer Fabienne Orsi, Christine Sevilla
and Benjamin Coriat; 12. Competition, regulation and intellectual property
management in GM foods: preliminary evidence from survey data Pierre
Regibeau and Katherine Rockett; 13. Governance, policy and industry
strategies: agro-biotechnology and pharmaceuticals Joanna Chataway, Joyce
Tait and David Wield; 14. The dynamics of knowledge accumulation,
regulation, and appropriability in the pharma-biotech sector: policy issues
Luigi Orsenigo, Giovanni Dosi and Mariana Mazzucato.
industry evolution Giovanni Dosi and Mariana Mazzucato; Part I. Innovation
and Industry Evolution: 2. Pharmaceutical innovation as a process of
creative destruction Frank Lichtenberg; 3. The evolution of pharmaceutical
innovation Paul Nightingale and Surya Mahdi; 4. Firm and regional
determinants in innovation models: evidence from biotechnology and
traditional chemicals Myriam Mariani; 5. Comments on Part I Lou Galambos;
Part II. Firm Growth and Market Structure: 6. Growth and diversification
patterns of the worldwide pharmaceutical industry Giulio Bottazzi, Fabio
Paolli and Angelo Secchi; 7. Heterogeneity in the firms' growth process:
the case of the pharmaceutical industry Elena Cefis, Matteo Ciccarelli and
Luigi Orsenigo; 8. Entry, market structure and innovation in a
history-friendly model of the evolution of the pharmaceutical industry
Christian Garavaglia, Franco Malerba and Luigi Orsenigo; 9. Comments on
Part II Boyan Jovanovic; Part III. Policy Implications: 10. Effects of
research tool patents and licensing on biomedical innovation John P. Walsh,
Ashish Arora and Wesley Cohen; 11. Upstream patents and public health: the
case for generic testing of breast cancer Fabienne Orsi, Christine Sevilla
and Benjamin Coriat; 12. Competition, regulation and intellectual property
management in GM foods: preliminary evidence from survey data Pierre
Regibeau and Katherine Rockett; 13. Governance, policy and industry
strategies: agro-biotechnology and pharmaceuticals Joanna Chataway, Joyce
Tait and David Wield; 14. The dynamics of knowledge accumulation,
regulation, and appropriability in the pharma-biotech sector: policy issues
Luigi Orsenigo, Giovanni Dosi and Mariana Mazzucato.
Figures; Tables; Contributors; 1. Introduction: innovation, growth and
industry evolution Giovanni Dosi and Mariana Mazzucato; Part I. Innovation
and Industry Evolution: 2. Pharmaceutical innovation as a process of
creative destruction Frank Lichtenberg; 3. The evolution of pharmaceutical
innovation Paul Nightingale and Surya Mahdi; 4. Firm and regional
determinants in innovation models: evidence from biotechnology and
traditional chemicals Myriam Mariani; 5. Comments on Part I Lou Galambos;
Part II. Firm Growth and Market Structure: 6. Growth and diversification
patterns of the worldwide pharmaceutical industry Giulio Bottazzi, Fabio
Paolli and Angelo Secchi; 7. Heterogeneity in the firms' growth process:
the case of the pharmaceutical industry Elena Cefis, Matteo Ciccarelli and
Luigi Orsenigo; 8. Entry, market structure and innovation in a
history-friendly model of the evolution of the pharmaceutical industry
Christian Garavaglia, Franco Malerba and Luigi Orsenigo; 9. Comments on
Part II Boyan Jovanovic; Part III. Policy Implications: 10. Effects of
research tool patents and licensing on biomedical innovation John P. Walsh,
Ashish Arora and Wesley Cohen; 11. Upstream patents and public health: the
case for generic testing of breast cancer Fabienne Orsi, Christine Sevilla
and Benjamin Coriat; 12. Competition, regulation and intellectual property
management in GM foods: preliminary evidence from survey data Pierre
Regibeau and Katherine Rockett; 13. Governance, policy and industry
strategies: agro-biotechnology and pharmaceuticals Joanna Chataway, Joyce
Tait and David Wield; 14. The dynamics of knowledge accumulation,
regulation, and appropriability in the pharma-biotech sector: policy issues
Luigi Orsenigo, Giovanni Dosi and Mariana Mazzucato.
industry evolution Giovanni Dosi and Mariana Mazzucato; Part I. Innovation
and Industry Evolution: 2. Pharmaceutical innovation as a process of
creative destruction Frank Lichtenberg; 3. The evolution of pharmaceutical
innovation Paul Nightingale and Surya Mahdi; 4. Firm and regional
determinants in innovation models: evidence from biotechnology and
traditional chemicals Myriam Mariani; 5. Comments on Part I Lou Galambos;
Part II. Firm Growth and Market Structure: 6. Growth and diversification
patterns of the worldwide pharmaceutical industry Giulio Bottazzi, Fabio
Paolli and Angelo Secchi; 7. Heterogeneity in the firms' growth process:
the case of the pharmaceutical industry Elena Cefis, Matteo Ciccarelli and
Luigi Orsenigo; 8. Entry, market structure and innovation in a
history-friendly model of the evolution of the pharmaceutical industry
Christian Garavaglia, Franco Malerba and Luigi Orsenigo; 9. Comments on
Part II Boyan Jovanovic; Part III. Policy Implications: 10. Effects of
research tool patents and licensing on biomedical innovation John P. Walsh,
Ashish Arora and Wesley Cohen; 11. Upstream patents and public health: the
case for generic testing of breast cancer Fabienne Orsi, Christine Sevilla
and Benjamin Coriat; 12. Competition, regulation and intellectual property
management in GM foods: preliminary evidence from survey data Pierre
Regibeau and Katherine Rockett; 13. Governance, policy and industry
strategies: agro-biotechnology and pharmaceuticals Joanna Chataway, Joyce
Tait and David Wield; 14. The dynamics of knowledge accumulation,
regulation, and appropriability in the pharma-biotech sector: policy issues
Luigi Orsenigo, Giovanni Dosi and Mariana Mazzucato.